Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
Open Access
- 24 November 2015
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (3) , 546-547
Abstract
Effective immune checkpoint blockades have improved the overall survival of patients with metastatic melanoma. The monoclonal antibody nivolumab blocks programmed cell death 1 (PD-1), an inhibitory immune checkpoint receptor expressed on activated T cells and B cells. Nivolumab is associated with a significant improvement in overall survival and progression-free survival and associated with a low risk of high-grade toxic effects [1]. Recent studies, however, showed that the immune activation caused by PD-1 blockade might promote severe autoimmune toxicity [2].Keywords
This publication has 5 references indexed in Scilit:
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trialThe Lancet, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- PD-1 deficiency reveals various tissue-specific autoimmunity by H-2band dose-dependent requirement of H-2g7for diabetes in NOD miceProceedings of the National Academy of Sciences, 2008
- Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responsesInternational Immunology, 1998